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Abstract
Introduction: Colorectal cancer is the fourth most common malignant disease. Of newly diagnosed patients, 40% have metastatic
disease at diagnosis, and approximately 25% of patients with localized disease at diagnosis will ultimately develop metastatic disease.
The benefits of systemic chemotherapy in the treatment of metastatic colorectal cancer over best supportive care have been
established. Panitumumab (ABX-EGF) is the first fully human monoclonal antibody developed for use in colorectal cancer that targets
the extracellular domains of epidermal growth factor receptor.
Aims: The goal of this article is to review the published evidence for the use of panitumumab in the treatment of metastatic colorectal
cancer to define its therapeutic potential.
Evidence review: The major evidence of panitumumab activity in colorectal cancer has appeared in meeting report abstracts. One
phase II study in monotherapy, one in combination with chemotherapy, and one phase III study have included only patients with
metastatic colorectal cancer.
Clinical potential: To date, in phase II clinical studies panitumumab has demonstrated antitumor activity in advanced, refractory
colorectal cancer. As monotherapy it resulted in a 10% response rate with 38% of patients having stable disease, and a 36% response
rate with 46% stable disease when combined with chemotherapy. A phase III study indicates a clinically significant advantage of
panitumumab as third-line monotherapy over best supportive care. Panitumumab appears to have a good tolerability profile, with no
maximum tolerated dose yet defined.
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Core evidence proof of concept summary for panitumumab in metastatic colorectal cancer
Outcome measure Emerging evidence
Efficacy Potential to use as monotherapy (at a dose of 6 mg/kg every 3 weeks) or in combination with chemotherapy 
(at a dose of 2.5 mg/kg once per week); stable disease achieved in up to 46% of patients, and progression-free survival 
of 2–10.9 months
Response rates Evidence of activity with a response rate between 10% and 36%
Biomarker expression Even in studies where immunohistochemistry expression of EGFR was required, it does not correlate with objective response
Tolerability Good toxicity profile; no maximum tolerated dose has been reported, and no differences in pharmacokinetic parameters
between the once weekly, every 2 weeks, and every 3 weeks dosage schedules
EGFR, epidermal growth factor receptor.Scope, aims, and objectives
Colorectal cancer is the fourth most common malignant disease
(IARC 2002; Meyerhardt & Mayer 2005) and the second leading
cause of cancer death in the USA (Jemal et al. 2005; Meyerhardt 
& Mayer 2005). Even though different therapeutic strategies with
new drugs have doubled the median overall survival (OS) of
metastatic colorectal cancer patients up to 21.5 months, it 
remains less than 2 years. Active salvage options are clearly
needed for this disease.
Panitumumab (ABX-EGF) is the first fully human monoclonal
antibody that targets the extracellular domains of epidermal
growth factor receptor (EGFR) to be investigated in colorectal
cancer. The objective of this review is to evaluate the potential role
of panitumumab in metastatic colorectal cancer. 
Methods
The English language medical literature was searched for relevant
articles related to the use of panitumumab in metastatic colorectal
cancer. The search terms used were “Panitumumab or ABX-EGF,”
“colorectal cancer” and the articles published covered a period
between 1988 to November 2006. The following databases 
were used:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez
• National Cancer Institute, http://www.cancer.gov 
• Clinical Evidence (BMJ), http://www.clinicalevidence.com 
• Clinical Trials, http://www.clinicaltrials.com 
The annual scientific sessions from the American Society of
Clinical Oncology (ASCO), European Society of Medical Oncology
(ESMO), American Association of Cancer Research (AACR), and
ASCO Gastrointestinal Cancers Symposium (ASCO GI) were
searched for relevant meeting abstracts. A total of 19 articles
were identified, 11 of those represented by systematic review.
Nine articles were excluded because they were considered not
relevant (Table 1). A further paper was identified (Van Cutsem et
al. 2007) replacing two earlier abstracts.
Few studies were identified for panitumumab use specifically in
colorectal cancer; this indication was however investigated in
early trials in which the drug was used in a variety of solid tumors.
No health economics publications were found. 
Disease overview
Colorectal cancer is one of the most common malignancies. 
The worldwide incidence estimated in 2002 was 1 023 152 
(550 465 men, 472 687 women) (IARC 2002). Of newly diagnosed
patients, 40% have metastatic disease at diagnosis, and
approximately 25% of patients with localized disease at diagnosis
will ultimately develop metastatic disease. With the exception of
patients with localized liver metastases, which is potentially
curable by surgical treatment, the majority of patients with
metastatic colorectal cancer die of their disease.
The essential element of the etiology of colorectal cancer is a
process of genetic change in the epithelial cells of the colonic
mucosa (Vogelstein et al. 1988). Epidemiologic factors have
provided initial evidence about specific factors that initiate 
the process of carcinogenesis in large bowel mucosa (Winawer &
Shike 1992). Chief among the factors that can initiate colorectal
cancer development are a predisposition to mutagen effects, fecal
mutagens, meat intake, bile acids, altered vitamin and mineral
intake, and fecal pH. Investigators are most suspicious of the role
of diet in causation of colorectal cancer (Peters at al. 1992). 
The incidence of the disease has been slowly declining over the
past few decades, probably because of improved screening and
earlier detection of premalignant disease. Colorectal cancer lends
itself to screening because of the long period between the
development of early mucosal abnormalities and the development
of invasive carcinoma. Adenomatous polyps are the well-
described precursor lesions of invasive colorectal cancer and can
be effectively managed by endoscopic intervention. In the general
population, the risk of development of a colorectal adenoma is
approximately 19%, and it is estimated that 2–5% of these
sporadic polyps will develop into an invasive carcinoma
(Ransohoff & Lang 1991). Unfortunately, adherence to screening
recommendations by individuals at average risk is suboptimal, 
and despite the ability to prevent colorectal cancer this 
disease remains a major cause of morbidity and mortality in 
western society.
Current therapy options
The treatment options for colorectal cancer depend on disease
stage at diagnosis. In locally advanced disease (stage I, II, III)
surgery is the most effective intervention. Even in cases of
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Category Number of records
Full papers Abstracts
Initial search 19 11
records excluded 9 3
records included 10 8
Additional studies identified 1 0
Level 1 clinical evidence 0 2
Level 2 clinical evidence 2 5
Level ≥3 clinical evidence 9 1
trials other than RCT 0 0
case reports 0 0
Economic evidence 0 0
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review83
metastatic colorectal carcinoma, surgery may be required for
palliation. The benefits of systemic chemotherapy in the
treatment of metastatic colorectal cancer have become
established in the past 20 years, and there is good evidence of
improved quality of life and OS (Simmonds 2000).
Fluorouracil has been considered the standard of care in the
past decade used both in advanced and in metastatic disease.
It has been used with and without biomodulating agents such as
leucovorin and methotrexate, alone as an intravenous bolus, by
high-dose weekly 24-hour infusions, or by protracted
continuous infusions which offer a higher response rate (33% vs
14%,  P=0.0004) (de Gramont et al. 1997). However,
progression-free survival (PFS) differs only modestly, being 
5 weeks longer with continuous infusion (P=0.001) and there is
no statistical benefit in terms of OS (de Gramont et al. 1997).
Capecitabine provides an oral alternative to intravenous
fluorouracil in both the metastatic and adjuvant setting. In two
separate phase III trials, capecitabine has demonstrated superior
response rate, equivalent PFS and OS, and decreased toxicity
compared with bolus fluorouracil/leucovorin (Hoff et al. 2001; Van
Cutsem et al. 2004).
The modern era of colorectal cancer chemotherapy began in the
mid-1990s when two novel chemotherapeutic agents—irinotecan
and oxaliplatin—were found to have significant activity in metastatic
colorectal cancer. The introduction of irinotecan and oxaliplatin has
nearly doubled the median survival of patients with metastatic
disease, replacing fluorouracil/folinic acid as the standard of care.
The consequence of the combination regimens using irinotecan
(Saltz et al. 2000) oxaliplatin (de Gramont et al. 2000) and
fluorouracil/folinic acid has been to increase the efficacy of first-line
therapy from response rates of about 20%, a time to progression of
4 months and a median OS of approximately 10 months in 1995, to
response rates of between 35% and >50%, a median time to
progression in the region of 8 months, and median OS of up to 21.5
months in 2004 (Tournigand et al. 2004). Although the combination
of oxaliplatin/fluorouracil/folinic acid (FOLFOX) demonstrated
significantly higher efficacy compared with irinotecan/fluorouracil
bolus/leucovorin (IFL), oxaliplatin/folinic acid (FOLOX) and
irinotecan/fluorouracil bolus + continuous infusion leucovorin
(FOLFIRI) appear to be equivalent in terms of efficacy. A phase III trial
comparing FOLFIRI and FOLFOX6 (oxaliplatin/fluorouracil/folinic
acid) with crossover at progression, found that response rate (56%
vs 54%), PFS (8.5 vs 8.1 months), and OS (21.5 vs 20.6 months)
were nearly identical (Tournigand et al. 2004).
Recently, targeted therapy has presented the opportunity to
improve on the efficacy of current treatments without
exacerbating the associated toxicity; the advent of monoclonal
antibodies has added improvements in survival and costs in
metastatic colorectal cancer. Attention has focused on EGFR and
on vascular endothelial growth factor (VEGF), which is implicated
in angiogenesis.
Angiogenesis is the process of new blood vessel formation and it
is considered critical for tumor growth. Unlike traditional
chemotherapy, angiogenesis inhibitors specifically target the
formation of new blood vessels without interfering with dividing
hematopoietic stem cells or gastrointestinal cells. At the time of
writing, bevacizumab (Avastin®), a humanized antibody directed
against VEGF, has been approved in the USA and in Europe for
first-line therapy in metastatic colorectal cancer. Approval was
based on a phase III pivotal trial that evaluated the activity 
of bevacizumab 5 mg/kg every 2 weeks when added to IFL, 
the standard care in the USA. Significant differences in PFS 
(10.6 vs 6.2 months) and OS (20.6 vs 15.6 months) were
registered in the bevacizumab-containing arm. Improvement in
response rate (45% vs 35%) was moderate, maybe because the
angiogenesis inhibitors mainly result in tumor growth inhibition
rather than regression (Hurwitz et al. 2004). The Eastern
Cooperative Oncology Group (ECOG) trial E3200 has evaluated
the activity of bevacizumab in combination with oxaliplatin and
fluorouracil as second-line therapy. The final results, presented 
at the ASCO meeting 2005, showed an advantage (12.5 vs 
10.7 months) in terms of OS, with a reduced hazard ratio for death
of 0.73 (Giantonio et al. 2005).
Another potential target in colorectal cancer treatment is EGFR, a
cell membrane growth factor receptor with tyrosine kinase activity
which plays a crucial role in the control of key cellular
transduction pathways in both normal and cancer cells. The
EGFR is overexpressed in a variety of human tumors, including
colorectal, head and neck, breast, lung, prostate, kidney,
pancreas, ovary, brain, and bladder cancers (Woodburn 1999;
Mendelsohn & Baselga 2000). Functional activation of EGFR is
due to the formation of either EGFR-EGFR homodimers or of
heterodimers with one of the other three members of the EGFR
family of growth factor receptors (HER-2, HER-3, and HER-4)
following binding of an EGFR-selective ligand, such as EGF,
transforming growth factor alfa (TGF-alfa), or amphiregulin. This
results in conformational changes that allow activation of the
EGFR tyrosine kinase with the phosphorylation of specific
tyrosine residues within the EGFR intracellular carboxyl-terminal
domain. Phosphorylated tyrosine residues serve as docking sites
for several signaling proteins that initiate a complex intracellular
signal transduction cascade that ultimately affects regulation of
gene transcription (Yarden 2001; Yarden & Sliwkowski 2001). The
activity of EGFR could be neutralized by monoclonal antibodies
that bind to the extracellular domain and competitively inhibit
ligand binding to prevent receptor dimerization and subsequent
activation of the receptor tyrosine kinase. The EGFR-monoclonal
antibody complex is internalized, causing a transient decrease in
EGFR expression (Ciardiello & Tortora 2001). Eighty percent of
colorectal cancers are EGFR-positive by immunohistochemistry
staining (Cunningham et al. 2004). This parameter does not
correlate with clinical response and, moreover, even EGFR
immunohistochemistry-negative tumors could respond to EGFR
inhibitor treatment (Chung et al. 2005).
Cetuximab (Erbitux®) is a chimeric human monoclonal antibody
against EGFR, approved worldwide in metastatic colorectal cancer
refractory to irinotecan-based therapy. Cetuximab is typically
administered at 400 mg/m2 initially, followed by 250 mg/m2 weekly
thereafter. The first phase II nonrandomized trials attested to its
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and in combination with IFL (response rate 19%, stable disease
27%) in patients who had failed prior irinotecan therapy (Saltz et
al. 2001, 2004). These results were confirmed in a large,
randomized, phase III trial carried out in 329 patients, of whom 
218 received cetuximab plus irinotecan and 111 cetuximab alone
(Cunningham et al. 2004). The response rate with the combination
was significantly higher than with monotherapy (23% vs 11%,
P=0.007). Disease control rates were 56% and 32%, respectively,
and time to progression was also significantly greater for the
combination arm (4.1 vs 1.5 months, P<0.001). The median
survival time was 8.6 months in the cetuximab arm (P=0.48).
The role of cetuximab combined with FOLFOX4
(oxaliplatin/fluorouracil/leucovorin) in a first-line setting has been
tested in a phase II trial of 43 patients. A total of 9% of patients
achieved a complete remission and 63% had partial response,
with an overall confirmed response rate of 72%. Ten patients
underwent liver metastasectomy, the overall response rate was
81%, and the PFS was 10.2 months (Dìaz Rubio et al. 2005). More
information about the role of EGFR inhibition as a first-line option
in colorectal cancer should come from the Crystal study, a large
multicenter study in which 1212 patients with previously
untreated metastatic colorectal cancer expressing EGFR have
been randomized to receive FOLFIRI with or without cetuximab;
preliminary data are expected in 2007. 
These interesting results have led to investigation of the
combination between EGFR inhibitors and antiangiogenic agents.
The preliminary results of a randomized phase II study in patients
with irinotecan-refractory, metastatic colorectal cancer have 
been reported. In this trial, named the BOND-2 study, 39 patients
were treated with the combination of cetuximab, irinotecan, and
bevacizumab, and 35 patients received cetuximab plus
bevacizumab treatment. The authors have reported a 37%
response rate with a time to progression of 7.9 months in 
the triple-drug combination, compared with 20% and 5.6 months
in patients treated with cetuximab plus bevacizumab 
(Saltz et al. 2005).
Targeted therapy represents a new frontier in treatment 
of colorectal cancer. New compounds such as panitumumab
could have the same efficacy as cetuximab with lower 
incidence of hypersensitivity reactions due to it being a fully 
human antibody.
Outcomes achieved in clinical development
Panitumumab is being evaluated in clinical trials as both a
monotherapy and in combination with other agents for the
treatment of various types of cancer including colorectal, lung,
and kidney.
Several phase II studies with panitumumab have been carried out,
and other phase III trials are ongoing. An important difference
compared with cetuximab is that panitumumab is a fully human
Ig2 monoclonal antibody created by Abgenix’s XenoMouse
technology, which creates antibodies that contain no murine
protein (Mendez et al. 1997). The goal of this technique is to offer
effective high-affinity therapy with a minimum of allergic reactions
or anaphylaxis.
Monotherapy
Until now, 1130 patients have been treated with panitumumab as
monotherapy, including 789 with metastatic colorectal cancer,
229 of whom have been enrolled in a phase III trial. The remaining
341 patients had renal cell carcinoma and other solid tumors.
The phase I data of safety, pharmacokinetics, and antitumor
activity in solid tumors were presented at the ASCO meeting 2005
(Weiner et al. 2005). In this study sequential cohorts of patients
were enrolled to receive four infusions at different dose levels 
and schedules of panitumumab monotherapy ranging from 
0.01 to 5 mg/kg once per week, to 6 mg/kg once every 2 weeks,
or 9 mg/kg once every 3 weeks. Patients were prescreened for
EGFR expression by immunohistochemistry and had to have at
least 1+ (defined as low staining intensity) expression in ≥10% of
tumor cells. A total of 96 patients were enrolled; tumor types
included 39 colorectal, 21 prostate, 15 renal, 14 nonsmall cell lung
(NSCLC), three pancreatic, three esophageal/gastroesophageal,
and one anal cancer. Pharmacokinetic exposure was similar
between 2.5 mg/kg per week, 6 mg/kg every 2 weeks, and 9 mg/kg
every 3 weeks.
By investigator assessment, five patients had a partial response,
all of whom had colon cancer and 19 had stable disease including
eight with colorectal cancer, five with NSCLC, three with prostate
cancer, two with renal cancer, and one with gastroesophageal
cancer. The incidence of skin-related toxicities was dose
dependent and reached a plateau at >2.0 mg/kg once per week.
Grade 3 or 4 related adverse events were noted in 10% of
patients with grade 3 skin-related effects being the most frequent
(7% of patients). No maximum tolerated dose was reached, and
no human antihuman antibody formation or infusion-related
reactions was observed.
A phase II open-label trial presented at the ASCO meeting 2004
(Hecht et al. 2004; Malik et al. 2005) assessed the efficacy of
panitumumab monotherapy in patients with metastatic colorectal
cancer who failed therapy with a fluoropyrimidine, fluorouracil 
(± leucovorin), and either irinotecan or oxaliplatin. A total of 
150 patients were enrolled and received at least one dose of
panitumumab; 148 were included in the safety and efficacy
analysis. Patients were subdivided into two cohorts according to
immunohistochemistry tumor staining. Cohort A included patients
with EGFR 2+ (defined as moderate staining intensity by
immunohistochemistry) or 3+ (defined as high staining intensity
immunohistochemistry) in ≥10% tumor cells; cohort B included
patients with EGFR of the sum of 1+, 2+, and 3+ in ≥10% of tumor
cells, but with the sum of 2+ and 3+ in <10% of tumor cells.
Panitumumab was given intravenously at 2.5 mg/kg once weekly
in 8-week cycles; patients continued treatment until disease
progression or unacceptable toxicity. Panitumumab monotherapy
resulted in a 10% response rate with stable disease in 38% 
of patients; the median duration of response was 5.2 months
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[95% confidence interval (CI) 4.5, 7.5 months]. The median PFS
was 2 months (95% CI 1.9, 3.8 months), and the median survival
amounted to 7.9 months (95% CI 5.7, 9.9 months). The four most
frequently reported grade 3 or 4 treatment-related adverse effects
were rash, fatigue, vomiting, nausea, and pruritus. Skin-related
adverse events were reported in 141 patients (95%; 5% grade 3
and no grade 4). One infusion-related grade 3 adverse event was
registered but no dose modification was required. No human
antihuman antibodies were observed. A relationship between skin
rash severity and survival seems to be similar to that noted with
the use of cetuximab (Hecht et al. 2006b). Moreover, its efficacy
appears to be similar in patients with both low and negative EGFR
levels (Hecht et al. 2006a, 2007).
This has been confirmed by a multicenter, single-arm, phase II
study that enrolled patients with low (defined as 1–9% of tumor
membrane staining by immunohistochemistry) or negative (<1%
tumor membrane staining) EGFR levels. Patients had failed 2–3
prior regimens containing an adequate dose of fluoropyrimidine,
irinotecan, and oxaliplatin; they received panitumumab at the
dose of 6 mg/kg every 2 weeks. Tumor assessments were taken
from week 8 until disease progression and were performed by an
independent eligibility review committee. The interim analysis
included 89 patients, 57% of whom were male, and with a median
age of 61 years. Six of thirty-five (2%) partial responses were
reported in patients with low expression of EGFR (<1%) and 4/51
(8%) in patients with negative levels of EGFR, and stable disease
occurred in 11/35 (31%) versus 15/51 (29%), with a disease
control rate of 37% versus 39%. Time to progression was 
9 weeks for both low or negative EGFR patients, with duration of
response of 31 versus 20 weeks, and PFS of 7 versus 8 weeks.
The most common adverse events were dermatitis acneiform
(72% in total, 6% grade 3/4), erythema (69%, 6%), pruritus (65%,
4%), and hypomagnesemia (53%, 10%). Three patients (<3%) had
an infusion reaction per investigator (one grade 3 infusion
reaction). The overall response rate was judged the same in the
local and in the central review committee (Hecht et al. 2007). 
The activity of panitumumab has also been tested in patients with
metastatic colorectal cancer expressing ≥10% EGFR. Patients with
documented disease progression during or following adequate
doses of fluoropyrimidine, irinotecan, and oxaliplatin regimens
received panitumumab 6 mg/kg every 2 weeks until disease
progression. Study endpoint was objective response rate (ORR) at
week 16. In the interim analysis, 91 enrolled patients received more
than one dose of panitumumab. The efficacy set consisted of 23
male and 16 female patients, median age 58.6, 95% ECOG score
≤1, 74% with colon cancer, and 26% with rectal cancer. At week
16, three patients (8%) had a partial response, eight (21%) had
stable disease, and 19 (49%) had disease progression. Response
durations were 12.4, 13.2, and 14.0 weeks. As main adverse events
skin toxicity was reported in 96% of the cases, 8% for nail and 5%
for eye toxicity, 27% for diarrhea, and 12% for hypomagnesemia.
One patient had a grade 3 hypersensitivity reaction related to
panitumumab (Berlin et al. 2006).
A large, phase III, multicenter, pivotal trial (study 408) has
randomized patients with oxaliplatin and irinotecan-refractory
EGFR-expressing metastatic colorectal cancer between best
supportive care (BSC) and BSC plus panitumumab at a dose of 
6 mg/m2 every 2 weeks (Van Cutsem et al. 2007). The aim of this
pivotal trial was to show a significant difference in PFS. A total of 
1040 patients were screened, of whom only 463 were randomized
(1:1); 231 received panitumumab with BSC, 232 received BSC only,
174 patients received panitumumab under crossover protocol.
Patients were stratified for sex, age, ECOG performance status,
number of metastatic sites, prior chemotherapy, and intensity of
EGFR staining. Panitumumab showed a 46% decrease in tumor
progression rate versus BSC alone (hazard ratio 0.54; 95% CI 0.44,
0.66; P<0.000000001, stratified log-rank test). The subset analyses
demonstrated consistent treatment effect of panitumumab in all
subgroups of patients. The response rate was significantly higher in
the panitumumab arm, with 8% partial response rate and 28%
achieving stable disease, compared with no partial responses and
10% stable disease with BSC alone. The time to response was 
8 weeks, and the median duration of the response was 17 weeks.
Panitumumab also showed activity in crossover study patients with
10% achieving partial response and 32% stable disease. 
Skin reactions of any grade occurred in 90% of patients receiving
panitumumab, and in 9% of those receiving BSC; the incidence of
grade 3–4 skin-related adverse reactions was 14% and 0% for
panitumumab and BSC, respectively. Skin reactions consisted 
of dermatitis acneiform 7%, erythema 5%, pruritus 2%, and 
rash 1%.
Overall, 33% of patients in the panitumumab arm experienced
grade 3 adverse effects, mainly due to abdominal pain (23% vs 17%
with BSC alone), fatigue (24% vs 15%), nausea (22% vs 15%),
diarrhea (21% vs 11%), and 2% of all patients experienced grade 4
toxicity. Hypomagnesemia occurred in 38% of patients treated with
panitumumab versus 2% of those in the BSC arm; the patients with
grade 3–4 toxicity (3% in both groups) received intravenous
magnesium. The incidence of potential infusion reactions was low
with no grade 3–4 reactions. Only one grade 2 hypersensitivity
reaction was reported and treatment was discontinued (Van Cutsem
et al. 2007).
Recently, data have been presented from the exploratory efficacy
analyses from this trial of PFS, ORR, and OS in patient subsets
based on baseline performance status (ECOG score 0–1 vs 2–3)
and age (<65 vs ≥65 years). Most had ECOG score of 0–1 (87%
panitumumab, 84% BSC); 42% of panitumumab patients and
39% of the BSC group were aged ≥65 years. The treatment effect
on PFS favored panitumumab regardless of age or ECOG status.
Among the panitumumab patients, similar PFS, OS, and ORR
were seen between elderly and younger patients and within both
ECOG status groups (Van Cutsem et al. 2007).
Combination therapy
There are also data showing good activity as first-line treatment of
metastatic colorectal cancer when panitumumab 2.5 mg/kg once
weekly is combined with chemotherapy. These data are from a
two-part phase II study, in the first part of which panitumumab is
added to IFL. 
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disease was stable in 26%, with a median PFS of 5.6 months and
median OS of 16.8 months (Berlin et al. 2004). The rate of early
disease progression was slow and was experienced in only one
patient; all patients who responded to the panitumumab
combination developed skin rash. The second part of this study
enrolled patients with the same characteristics (n=24) but they
received panitumumab with FOLFIRI as first-line chemotherapy. 
The primary endpoint of the study was the incidence of 
diarrhea; the secondary endpoints included ORR, PFS, and OS.
Thirty-three percent of patients achieved partial response and
46% had stable disease, with a PFS of 10.9 months. The median
OS was not reached because at the time of analysis (May 2005)
23 of 24 patients were still alive (Hecht et al. 2006b). The
incidence of grade 3 and 4 diarrhea was 53% and 5%,
respectively, for part 1 of the study, and 25% and 0%,
respectively, in part 2. Treatment-related skin reactions were
present in both parts, reaching grade 3 severity in 16% of patients
in part 1 and in 17% of patients in part 2; there were no grade 4
reactions. Other grade 3 treatment-related adverse events
included hypokalemia (16%), fatigue (11%), and nausea (5%) in
part 1; none of these events occurred in part 2. Grade 4
treatment-related hypomagnesemia occurred in one patient in
each part of the study. There were no severe infusion reactions, or
human antihuman antibody formation (Berlin et al. 2004; Hecht 
et al. 2006b). 
The activity of panitumumab in combination with FOLFIRI and
AMG706 was tested by Burris and colleagues (2007). AMG706 is
an oral, multikinase inhibitor with antiangiogenic activity that
selectively targets VEGF, PDGF (platelet-derived growth factor),
and Kit receptors. In this ongoing phase I study panitumumab
was given at a dosage of 6 mg/kg by intravenous infusion every 
2 weeks, and AMG706 was given continuously from day 3 of
cycle 1 in escalating doses; patients also received either FOLFOX
or FOLFIRI based on prior systemic therapy. Dose-limiting toxicity
was assessed during the first two cycles, and tumor response
was evaluated every 6–8 weeks from week 6. At the time of
writing, data are available only for the cohort containing FOLFIRI.
Twenty-two patients were enrolled and had received at least one
dose of AMG706 at the time of data cut-off (50 mg, n=12; 75 mg,
n=7; 100 mg, n=3), including 11 men and 11 women, with median
age of 53 years. There were two dose-limiting toxicities of
AMG706, represented by diarrhea (50 mg) and deep vein
thrombosis (75 mg). These preliminary data show that
coadministration of FOLFIRI, panitumumab, and AMG706 is safe,
with little effect on the pharmacokinetics of AMG706 at a dose of
50 mg (Burris et al. 2007). 
Ongoing studies
Several studies are ongoing in metastatic colorectal cancer utilizing
panitumumab in combination with other chemotherapeutic agents
or with targeted therapy in first-, second-, and third-line treatment.
One of the largest is PACCE (Panitumumab Advanced Colorectal
Cancer Evaluation), which is a multicenter trial in the US 
in which more than 1000 patients were randomized for first-line
treatment of metastatic colorectal cancer with chemotherapy
(FOLFOX or FOLFIRI) plus bevacizumab ± panitumumab;
recruitment was initiated in 2005 and was concluded in 
September 2006. The preliminary analysis showed a statistically
significant difference in favor of the control arm, with an increase in
toxicity in the panitumumab-containing arm (Anon. 2007).
Patient group/population
Panitumumab is approved in the US for the treatment of patients
with EGFR-positive metastatic colorectal cancer with disease
progression on, or following, fluoropyrimidine-, oxaliplatin-, and
irinotecan-containing chemotherapy. The drug is not approved in
the EU.
Panitumumab is a fully human monoclonal antibody that targets
the extracellular domains of EGFR. To date in all trials with
panitumumab EGFR immunohistochemistry expression was
assessed. Response to treatment was seen in patients with
metastatic colorectal cancer with both low and negative EGFR
levels (Hecht et al. 2006a, 2007). This retrospective analysis
confirmed that skin rash could correlate with clinical response but
not with survival. However, despite this finding, regulatory
authorities have not reached a decision that could restrict
continued dosing with panitumumab in patients who do not
experience skin rash. Rash associated with panitumumab is
common and can be classified according to the clinical
dermatological manifestations, requiring specific treatment
strategies (Mitchell et al. 2007).
Clinical potential
Within the last few years the natural history of metastatic
colorectal cancer treatment has changed, with a dramatic
improvement in OS especially with the combined modality
therapy of conventional chemotherapy plus biologic agents that
target a specific protein involved in tumor growth. Panitumumab
has shown clear activity in metastatic colorectal cancer as a
single agent and in combination chemotherapy. Panitumumab is
well tolerated, with the main toxicity being skin reactions,
although grade 4 severity has not been observed; no maximum
tolerated dose has been reported. Because it is a fully human
antibody, infusion-related reactions have been minimal; only
1/148 patients experienced a grade 3 reaction and 1/463 patients
discontinued treatment due to grade 2 hypersensitivity reaction in
clinical trials conducted to date. Another potential advantage of
panitumumab lies in its relative ease of use, with pharmacokinetic
parameters unaffected by administration every week, or every 
2 or 3 weeks. 
Encouraging results from trials reported so far demonstrate a
potential therapeutic value of this agent, but the data need to be
confirmed in large multicenter trials that explore the role of
panitumumab as a first- as well as a second-line option in
colorectal cancer.
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